News

Driving down drug prices: how regulators can influence affordability

Published on 2017/05/03

In recent years there has been increasing global concern over drug prices and their affordability. And what is the role played by regulators in drug pricing? This is the subject of discussion in a...

4 views

Read more →

EMA adopts new guidance on monitoring of biologicals

Published on 2017/04/28

The European Medicines Agency (EMA) announced on 15 August 2016 that it had introduced a new guideline on the monitoring of biologicals, including biosimilars. The European Union introduc...

11 views

Read more →

Sandoz plans to launch five more biosimilars by 2020

Published on 2017/04/26

Sandoz, the generics division of Novartis, has announced plans for five major global biosimilar launches by 2020. The company says that five biosimilar launches are realistic based on its...

5 views

Read more →

The satisfaction of healthcare payers, patients and physicians with generic imatinib

Published on 2017/04/24

With the begining of the era of tyrosine kinase inhibitors (TKIs), chronic myeloid leukaemia (CML) became a chronic disease, in which good responding patients usually have a life expectancy simila...

9 views

Read more →

Pure red cell aplasia in a CKD patient after treatment with epoetin zeta

Published on 2017/04/21

Authors from the Versilia and Manzoni Hospitals in Italy report the case of a patient who developed pure red cell aplasia (PRCA) following subcutaneous administration of epoetin zeta, which is one...

7 views

Read more →

Ways to reduce drug costs in Australia

Published on 2017/04/19

Drug costs in Australia are increasing at an alarming rate. This is driven mainly by expensive biological therapies, antiviral therapies for HIV and hepatitis C and new cancer treatments. ...

3 views

Read more →

Doctors want more details in biosimilars labelling

Published on 2017/04/12

In the European Union (EU), labels (Summaries of Product Characteristics, SmPCs) for biosimilars and their reference products are, in many instances, almost identical despite different data requir...

2 views

Read more →

AES position statement on substitution of generic anti-epileptics

Published on 2017/04/12

A paper by the American Epilepsy Society (AES) discusses how the society’s position on generics substitution of anti-epileptic drugs has changed according to the results of bioequivalence studie...

2 views

Read more →

Biosimilar rituximab in biological naïve rheumatoid arthritis patients

Published on 2017/04/10

Cost remains a major constraint in the use of originator biologicals in rheumatology in developing countries, paving the way for ever increasing usage of biosimilars. However, apart from the cost,...

1 views

Read more →

Reasons for the success of a generics company in the Sudan market

Published on 2017/04/07

An exploratory, qualitative study carried out by colleagues from the University of Khartoum (Sudan) and Abertay University (UK) examined the reasons behind the success of a generics company that h...

2 views

Read more →

Immunogenicity of biologicals: the role of post-translational modifications

Published on 2017/04/05

Although produced under strict quality control(s) nascent endogenous proteins and glycoproteins (P/GP) are structurally heterogeneous and subject to further structural changes throughout their in ...

3 views

Read more →

Pharmacists prefer generic OTC medicines

Published on 2017/04/03

In the US, the use of generics has been lacking due to hesitation from consumers over whether generics are as safe and effective as brand-name medications. Pharmacists, on the other hand, have the...

5 views

Read more →